Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
  • C08J11/00—Recovery or working-up of waste materials
  • C08J11/04—Recovery or working-up of waste materials of polymers
  • C08J11/06—Recovery or working-up of waste materials of polymers without chemical reactions
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
  • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
  • B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
  • B09B3/30—Destroying solid waste or transforming solid waste into something useful or harmless involving mechanical treatment
  • B09B3/35—Shredding, crushing or cutting
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
  • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
  • B09B2101/00—Type of solid waste
  • B09B2101/65—Medical waste
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
  • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
  • B09B2101/00—Type of solid waste
  • B09B2101/65—Medical waste
  • B09B2101/68—Transdermal patches
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
  • Y02W30/00—Technologies for solid waste management
  • Y02W30/50—Reuse, recycling or recovery technologies
  • Y02W30/62—Plastics recycling; Rubber recycling

Definitions

• the invention relates to a process for the recovery of medicinal or active substances from preparations, their precursors or waste, in particular in the form of flat starting material, containing an adhesive-coated film and a substance containing an active substance.
• Active substances from unused or stored devices for the transdermal application of active substances and / or their production wastes are particularly suitable for this, the active substances contained therein usually being present in conjunction with polymer films or polymer films.
• Devices for transdermal application can be divided into two categories: a) systems which release active substances to the skin or the organism by passive diffusion and b) systems which active substances under the action or with the support of electrical currents to the skin or give up the organism.
• TTS transdermal therapeutic systems
• active ingredient is dissolved in polymer films or partially crystalline or suspended in the form of microcapsules.
• such systems therefore consist of an active substance-impermeable backing layer, an active substance-containing and preferably self-adhesive matrix and a protective film to be removed before use.
• Reservoir systems contain active ingredient in a liquid reservoir. It can be complete or only partially solved.
• such systems consist of a backing layer which is impermeable to the substances in the reservoir and a membrane which is at least permeable to the active ingredient and which is preferably equipped with an adhesive film for fastening the system to the skin.
• Systems that deliver the active ingredient to the skin or the organism using electrical current can have very different structures. They are particularly used for active ingredients that, due to their chemical-physical properties, cannot penetrate the skin in sufficient quantities through passive diffusion.
• DE-OS 42 21 681 describes a recycling process of polyethylene, polypropylene or polystyrene adhesives on label waste.
• DE-OS 40 37 562 describes recycling of plastic films coated with adhesive by repeated kneading in solvent, draining in a screw conveyor and repeated passage of remaining material by the same procedure. From this is also known a method for recycling adhesive-coated and shredded plastic films by separating the plastic material and the adhesive. In a first stage, the film chips are moved in a solvent for adhesive to disperse the adhesive adhering to the film chips with the solvent for a predetermined period of time under mechanical action. The adhesive dispersed in the solvent is then separated from the film chips by mechanical force. The film chips discharged from the first stage are fed with fresh solvent in a second, similar stage and the solvent-adhesive dispersion of the second stage is fed into the first stage.
• DE-OS 195 24 083 describes a recycling process for TTS in which the active ingredient is dissolved in a solvent and recovered from it.
• the disclosure is limited to the embodiment that the methods on which the invention is based are known to the person skilled in the art.
• this document suggests to a person skilled in the art to subject the TTS to a pretreatment in order to sort out the carrier and / or protective film packaging material etc.
• the object of the present invention is to demonstrate a method with which it is possible in an economically justifiable manner to dispose of waste medical preparations and in particular devices for transdermal application of unused or after storage Process active substances, so-called TTS, for the recovery of active substances contained therein.
• the problem is solved in a method according to claim 1 in accordance with the work steps and measures listed therein.
• the process is environmentally friendly, can be carried out economically, and on the one hand enables valuable raw materials to be obtained and, on the other hand, a fraction of residues from solids or carrier substances that is largely freed from ingredients, is environmentally neutral and therefore easy to dispose of.
• the carrier materials or residues from the process can be further recycled and disposed of using known methods.
• the process according to the invention avoids costly process steps such as e.g. the preparation of the materials in a pretreatment by sorting and separating them into sorted fractions, whereby foreign substances such as carrier and / or protective films are sorted out and the substance containing the active substance is concentrated.
• the separation takes place according to the invention by means of a complete solution of the active substances. Costly comminution, for example using a shredder, is not necessary, which is problematic due to the pressure sensitive adhesive properties even after embrittlement. Rather, the dissolution and thus the prerequisite for the extraction of active ingredient takes place in a liquid.
• the active ingredients are precipitated by shifting the pH.
• the solution obtained is filtered off and the drug is purified by salt formation and / or recrystallization
• the method is expedient, economically advantageous and optimally fulfills the task set out above.
• active substances with a hormone-like effect es radiol, estradiol derivatives, gestagens, gestagen derivatives or their mixtures, morphine or morphine derivatives, buprenorphine, physostig in, scopolamine, galanthamine can be recovered.
• the recovered substances can then be used again depending on their pharmaceutical effects as pain relievers and for the treatment of senile dementia, hypertension, arrhythmias, vascular diseases, addictions, increased blood lipid levels, mental disorders, for influencing blood clotting, eating disorders or disorders of the sugar metabolism.
• the invention is illustrated by the following examples:
• the protective film was not removed. No crushing took place.
• the protective film was a 100 .mu.m thick siliconized PET film, the backing layer a 15 .mu.m thick transparent PET film which partially dissolved when stirred. After stirring had ended, the film residues were separated by a sieve. The filtrate is diluted with sulfuric acid brought pH 1. Here estradiol and terephthalic acid fail. The two are separated from one another by stirring with acetone.
• Estradiol (and terephthalic acid) are precipitated at pH 1.
• Buprenorphine is precipitated from the filtrate by adding sodium hydroxide solution at pH 8. While the yield of estradiol corresponds to that of Example 4, that of buprenorphine is below that of Example 2, namely 26.

Landscapes

• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Polymers & Plastics (AREA)
• Sustainable Development (AREA)
• Health & Medical Sciences (AREA)
• Environmental & Geological Engineering (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Extraction Or Liquid Replacement (AREA)
• Processing Of Solid Wastes (AREA)
• Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=7854072

Family Applications (1)

Country Status (10)

Families Citing this family (2)

Citations (2)

Family Cites Families (2)

• 1998
  • 1998-01-07 DE DE1998100277 patent/DE19800277B4/de not_active Expired - Fee Related
  • 1998-12-31 TW TW87121941A patent/TW450842B/zh not_active IP Right Cessation
• 1999
  • 1999-01-05 JP JP2000527374A patent/JP4455754B2/ja not_active Expired - Fee Related
  • 1999-01-05 CA CA002317481A patent/CA2317481C/en not_active Expired - Fee Related
  • 1999-01-05 WO PCT/EP1999/000019 patent/WO1999034941A1/de not_active Ceased
  • 1999-01-05 US US09/582,377 patent/US6417365B1/en not_active Expired - Fee Related
  • 1999-01-05 AU AU24197/99A patent/AU741521B2/en not_active Ceased
  • 1999-01-05 EP EP99903603A patent/EP1045736A1/de not_active Ceased
  • 1999-01-06 ZA ZA9900071A patent/ZA9971B/xx unknown
  • 1999-01-06 MY MYPI9900032 patent/MY133056A/en unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events